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INTRODUCTION
Lyme borreliosis is a tick-borne infection caused by the spi-
rochete Borrelia burgdorferi (Nadelman, 2001; Wormser,
2006). At least three species of Borrelia burgdorferi sensu
lato (Borrelia burgdorferi sensu stricto, Borrelia garinii,
and Borrelia afzelii) can cause the disease.
Lyme disease is the most common vector-borne disease in
the United States and Europe, and its incidence is also high
in Latvia (Piacentino, 2002; Anonymous, 2014). During the
last five years (2010–2014), morbidity of Lyme borreliosis
in Latvia varied from 39.5 to 23.5 per 100 000 inhabitants
(829 to 469 people per year) (Table 1). The largest number
of cases of Lyme borreliosis was recorded in 2011 — 866
infected persons (Table 1). Latvia is considered to be an en-
demic territory for diseases, but people may become af-
fected in other countries of the world.
In Europe, Lyme disease is caused by infection by one or
more pathogenic European genospecies of the spirochaete
B. burgdorferi sensu lato, mainly transmitted by the tick
Ixodes ricinus (Piacentino, 2002; Anonymous, 2014). Cases
of B. burgdorferi sensu lato-infected ticks are found pre-
dominantly in central Europe, particularly in Slovenia and
Austria, but have been isolated in almost every country on
the continent (Piacentino, 2002; Anonymous, 2014). Inci-
dence in southern Europe, Italy and Portugal, for example,
is much lower (Piacentino, 2002; Anonymous, 2014). The
incidence in children was shown to be higher than in adults
in European studies (Piacentino, 2002).
The disease usually begins with erythema migrans accom-
panied by viral-like or meningitis-like symptoms. A week
later, meningitis, facial palsy, atrioventricular nodal block,
or migratory musculoskeletal pain may develop, followed
months to years later by episodes of frank arthritis, en-
cephalopathy, polyneuropathy, or acrodermatitis (Abra-
mowicz, 2000; Auwaerter, 2004; Fleming, 2004; Au-
waerter, 2007).
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In this study, we sought to identify human leukocyte antigen (HLA) DRB1 alleles that might be as-
sociated with Lyme borreliosis in Latvian patients. Case patients and control subjects were similar
in age, sex, and ethnic heritage and differed only in the presence of Borrelia burgdorferi infection.
The frequency of HLA-DRB1*07 (OR 3.52; p = 0.001), HLA-DRB1*15 (OR 3.02; p = 0.001) and
HLA-DRB1 *17 (03) (OR 2.63; p = 0.001) were significantly increased in the Lyme disease pa-
tients compared with the control groups. The frequency of the alleles -DRB1*11(OR 0.37; p =
0.005) and -DRB1*13 (OR 0.34; p = 0.002) was smaller in Borreliosis patients and significantly
higher in the control group.
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T a b l e 1
NUMBER OF BORRELIOSIS CASES (PER 100 000 INHABITANTS
AND ABSOLUTE COUNT) IN LATVIA AS REPORTED TO THE
CENTER OF DISEASE PREVENTION AND CONTROL (CDPC) OF
LATVIA
Years 2010 2011 2012 2013 2014
Latvia, absolute count 829 866 724 454 469
Latvia, per 100 000 inhabitants 39.5 42.0 35.6 22.6 23.5
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Musculoskeletal and neurologic sequelae may occur from
Lyme disease. Some of the late consequences of Lyme dis-
ease, such as oligoarticular arthritis, axonal polyneuropathy,
or active encephalopathy, are thought to be caused by per-
sistent spirochetal infection and are amenable to antibiotic
treatment (Halperin, 2003; Wormser, 2003; Coulter et al.,
2004; Halperin, 2004). Other syndromes such as persistent
arthritis, fibromyalgia, subtle joint pain, or mild encephalo-
pathy do not improve with antibiotic treatment, suggesting a
mechanism other than active infection (Fleming, 2004;
Feder, 2007; Halperin, 2007).
The majority of individuals with treatment-resistant Lyme
disease have the HLA-DRB1*0401 or HLA-DRB1*0101 al-
lele, alleles which also occur more frequently in patients
with rheumatoid arthritis (Philipp, 2005; Feder, 2007; Oksi,
2007). Furthermore, while Borrelia burgdorferi DNA can
be detected in joint fluid of Lyme disease patients by PCR
prior to treatment with antibiotics, it is unusual to detect
such DNA in synovium or synovial fluid after antibiotic
treatment (Bateman, 2000; Qureshi, 2002). These findings
suggest that the pathogenesis of joint disease in chronic
Lyme arthritis may be a result of antibody directed against a
component of the B. burgdorferi spirochete that cross-reacts
with synovial tissue.
B. burgdorferi sensu lato is a Gram-negative spirochete.
The molecular typing of B. burgdorferi has been recently
reviewed in detail (Bunikis, 2002). While all three species
occur in Europe, only B. burgdorferi sensu stricto occurs in
the United States. It has been suggested that the different
clinical manifestations were caused by distinct species of B.
burgdorferi sensu lato. Based on DNA amplification, the
late dermatologic manifestation acrodermatitis chronica
atrophicans (ACA), which is observed in Europe but rarely
in the United States, was mostly associated with B. afzelii
(Nadelman, 2001; Wormser, 2000 ). Neuroborreliosis is fre-
quently but not exclusively caused by B. garinii (Halperin,
2003; Halperin, 2005), and all three species have been de-
tected in synovial fluid samples from patients with Lyme
arthritis (Steere, 2001; Steere, 2003; Steere, 2006; Stricker,
2007). The first suggestion that antibiotic-refractory Lyme
arthritis might have an autoimmune component was the
demonstration of its association with the HLA–DR4 and
HLA–DR2 alleles (Steere, 2003). Patients who have
HLA–DR4 and HLA–DR2 molecules, which bind an epitope
of B. burgdorferi outer surface protein A (OspA163–175),
are more likely to have antibiotic-refractory arthritis than
the patients with other DRB molecules (Sikand, 2001). Mo-
lecular techniques have identified the OspA163–
175-binding molecules as the rheumatoid arthritis alleles
(DRB1*0401, 0404, 0405, 0101, 0102) (Steere, 2006;
Wormser, 2006) and the DRB5*0101 allele linked to
DRB1*1501 (the former DR2 allele) (Steere, 2006). More-
over, patients with antibiotic-refractory arthritis often have
T cell recognition of OspA163–175 (Steere, 2006;
Wormser, 2006). Many autoimmune diseases are linked to
variants of HLA genes such as those encoding the MHC
class II complex. Antibiotic-refractory Lyme arthritis is as-
sociated with MHC class II variants that are able to bind to
fragments of the B. burgdorferi protein OspA (outer surface
protein A) encompassing amino acid residues 165 through
173 (Schoen, 2000). Antigen-presenting cells whose MHC
class II molecules display OspA163–175 peptides on their
surface stimulate T cells that recognize the OspA peptide.
How OspA163–175-reactive T cells cause autoimmunity
has been an area of intensive research, yet no clear answer
has emerged (Schoen, 2000).
The purpose of this study was to identify immunogenetic
markers of HLA DRB1 in patients with clinical, epidemio-
logical and laboratory approved Lyme borreliosis.
MATERIALS AND METHODS
DNA samples were obtained from 145 patients (58 males
and 87 females; aged between 35 and 74 years) with the
clinical stage of erythema migrans and 200 control
(healthy) persons (92 males and 108 females; aged between
21 and 57 years). The clinical diagnosis was confirmed at
the Infectology Centre of Latvia. Immunogenetic examina-
tions were performed at the Rîga Stradiòð University Clini-
cal Immunology and Immunogenetic Laboratory. Approval
of the Rîga Stradiòð University Ethics Committee was ob-
tained to perform this study, each participant signed an in-
formed consent to participation in this study.
Genomic DNA was extracted from proteinase-K-treated pe-
ripheral blood leukocytes using the routine “salting-out”
method (Halperin, 2005; Halperin et al., 2007). The DNA
was stored in TE buffer (10 ml Tris–HCl, pH 7.5, and 2 ml
0.5M Na² EDTA per litre of distilled water). The DNA con-
centration (about 100–200 µg/ml in most samples), was de-
termined using a fluorospectrometer NanoDrop 3300
(USA).
HLA-typing. HLA-DR genotyping for DRB1* 01 to *18,
was performed by PCR with sequence-specific primers
(PCR–SSP) (Klitz, 2003). The reaction mixture (15 µl) in-
cluded 1.0 µl DNA, 1.5 µl PCR buffer [50 mM KCl, 1.5
mM MgCl2, 10 mM Tris-HCl (pH 8.3)], 0.6 µl dNTPs (25
mmol/l), 1.0 µl specific primers (0.2 mmol/l), and 0.5 U of
the Taq DNA polymerase (Promega). The reaction mixture
was subjected to 35 amplification cycles, each consisting of
one denaturation cycle at 94°C (60 s), seven annealing cy-
cles at 94 °C (40 s) and 67 °C (15 s), and final 28 extension
cycles at 93 °C (10 s) and 65 °C (9 s). PCR products were
visualised by agarose-gel electrophoresis (Olerup, 1993;
Klitz, 2003). After addition of 2 M loading buffer, the PCR
reaction mixtures were loaded in agarose gels pre-stained
with ethidium bromide (0.5 µk/ml). Gels were run for 15
min at 10 V/cm gel in 0.5 mM TBE (0.89 M Tris, 0.89 M
boric acid and 0.02 M EDTA in aqueous solution) buffer
and then examined under UV illumination and recorded
(Olerup, 1993; Klitz, 2003).
Statistical analysis. The significance of differences in indi-
vidual subtypes between patients and controls was assessed
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by Mantel–Haenszel test and Fisher exact correction. Odds
ratios (OR), and 95% confidence intervals (CI) were com-
puted by standard methods (Anonymous, 2012).
RESULTS
Typing of all sixteen alleles DRB1 was conducted (Table 2).
Predisposition to Lyme disease was associated with the
HLA-DRB1*07 (OR 3.52; p = 0.001), HLA-DRB1*15(OR
3.02; p = 0.001) and HLA-DRB1 *17(03) (OR 2.63; p =
0.001) alleles (Table 2). For the DRB1 *02 and DRB1 *04
alleles, the evidence is controversial. The presence of DRB1
*02 and DRB1 *04 alleles in healthy persons and borreliosis
patients suggests lack of an association with Lyme disease.
However, the number of studied individuals was very low.
The distribution of alleles in the patients included in this
study followed the global patterns: HLA-DRB1 *04 and
DRB1 *17(03) are the most frequent alleles in the Cauca-
sian population. The HLA-DRB1*01, and DRB1*18(03) al-
leles were shown to be considerably increased in patients,
although the difference was not significant when the p value
was corrected for the number of alleles (Table 2). More-
over, the allele -DRB1*11(OR 0.37; p = 0.005) and
-DRB1*13 (OR 0.34; p = 0.002) was rarer in Borreliosis pa-
tients and significantly more frequent in controls.
This data suggest that HLA-DRB1 alleles may have a con-
siderable effect by susceptibility to Lyme borreliosis.
DISCUSSION
Numerous studies have established an association of HLA-
DR alleles with infectious and autoimmune diseases (Klitz,
2003). The various HLA-DR alleles, which are expressed on
thymic epithelial cells, as well as on antigen presenting
cells, have different peptide-binding requirements. The abil-
ity of the HLA-DR alleles to accommodate self- or disease-
associated peptides depends on the properties of the respec-
tive peptide-binding groove (Smith, 2002). Therefore, the
immune response against infectious agents, as well as sus-
ceptibility to autoimmune diseases, varies from one individ-
ual to another.
In our HLA study, an association was confirmed between
Lyme borreliosis and the HLA-DRB1 *07, and -DRB1
*17(03) (part of the former HLA-DR3) alleles. Secondary
association was noted with HLA-DRB1 *15 (part of the for-
mer HLA-DR2 and DR5 serotype groups). The distribution
of alleles in the patients included in this study follows the
global pattern: HLA-DRB1 *07 and DRB1 *17(03) were the
most frequent alleles in the Caucasian population (Kotsch,
1999).
One potential pathway to autoimmunity is molecular mim-
icry, in which a cross-reactive host protein in the joint con-
tinues to stimulate OspA163–175-specific T cells even after
the eradication of B. burgdorferi by antibiotics (Smith,
2002; Klitz, 2003; Steere, 2006). Although the simplicity of
the molecular mimicry model is appealing, exhaustive ef-
forts to find a cross-reactive autoantigen that stimulates
OspA163–175-specific T cells have failed (Smith, 2002;
Steere 2006). Moreover, levels of OspA163–175-reactive T
cells decline soon after initiation of antibiotic therapy de-
spite continuing arthritis following treatment.
Thus, chronic arthritis does not seem to involve molecular
mimicry driven by a cross reaction between the OspA163–
175 epitope and a self-antigen in the joint. It is possible that
molecular mimicry involves another B. burgdorferi antigen
that is able to bind the MHC class II variants found in ge-
netically susceptible individuals.
Numerous studies from USA and our HLA studies have
shown that HLA-DRB1*15 and -DRB1*0401 alleles are as-
sociated with chronic Lyme arthritis and lack of response to
antibiotic therapy (Steere, 2003; Auwaerter, 2007). This al-
lele is also associated with an increased risk of developing
severe rheumatoid arthritis (Hu, 2005). In a study of anti-
body responses in patients throughout the course of Lyme
disease, immunoglobulin G (IgG) responses to outer-surface
protein A (OspA) and OspB of the spirochete often devel-
oped near the beginning of prolonged episodes of arthritis
(Steere, 2003, 2006; Fallon, 2008). Arthritis lasted consid-
erably longer after treatment in patients with HLA-DR4 and
OspA and OspB antibody reactivity than in those who
lacked responses to these proteins (Seltzer, 2000; Nowa-
kowski, 2003). Persons with treatment-resistant Lyme ar-
thritis usually have T cells that react with many OspA
epitopes, whereas treatment-responsive patients usually do
not. A possible explanation for these findings is that the
T a b l e 2
THE FREQUENCY OF DRB1* ALLELES STUDIED IN PATIENTS










OR (95% CI) p
*01 28 31 1.27 [0.72–2.24] 0.377
*02 18 13 1.97 [0.90–4.34] 0.064
*03 19 29 0.90 [0.47–1.70] 0.721
*04 23 19 1.73 [0.88–3.38] 0.084
*07 35 15 3.52 [1.82–6.91] 0.001
*08 11 28 0.52 [0.24–1.12] 0.071
*09 9 29 0.41 [0.18–0.92] 0.018
*10 14 26 0.51 [0.26–1.01] 0.056
*11 10 35 0.37 [0.17–0.88] 0.005
*12 11 29 0.50 [0.23–1.07] 0.055
*13 10 38 0.34 [0.16–0.72] 0.002
*14 16 37 0.57 [0.30–1.09] 0.069
*15 38 19 3.02 [1.65–5.58] 0.001
*16 5 12 0.57 [0.17–1.76] 0.285
*17(03) 32 18 2.63 [1.40–5.00] 0.001
*18(03) 11 12 1.27 [0.52–3.14] 0.566
ND, not defined; OR, odds ratio, p, probability, significant associations for
p < 0.05. Bold-face type highlights statistically significant associations for
patients vs controls.
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T-cell response to OspA in patients with treatment-resistant
Lyme arthritis may cross-react with a self antigen in the
joint, and the response to this self antigen may continue to
cause joint inflammation for months or even years after the
eradication of the spirochete from the joint.
Treatment for patients with acute manifestations of Lyme
disease is well established and effective. Understanding the
pathophysiology of chronic neuroborreliosis and treatment-
resistant Lyme arthritis are both major challenges and a pre-
requisite for the eventual development of effective treat-
ments for these conditions.
The development of an effective vaccine against Lyme dis-
ease and the improved understanding of the long-term out-
come of Lyme disease can be considered the most important
advances in the field over the past several years.
CONCLUSIONS
In this study, we sought to identify HLA DRB1 alleles that
might be associated with Lyme borreliosis in Latvian pa-
tients. The inflammatory events of the subacute arthritis can
set the stage for development of chronic disease in individu-
als possessing an HLA susceptibility allele. In particular,
HLA-DRB1*07 (OR 3.52; p = 0.001), HLA-DRB1*15 (OR
3.02; p = 0.001) and -DRB1 *17 (03) (OR 2.63; p = 0.001)
contribute definitely to a genetic predisposition to Borrelia
burgdorferi infection in the Latvian population, which may
have implications in our understanding of pathogenesis of
this disease. The frequency of HLA-DRB1 *02 (OR 1.97;
p = 0.064); and HLA-DRB1 *04 (OR 1.73; p = 0.084) was
increased in the Lyme disease patients compared with the
control group. Moreover, the allele -DRB1*11(OR 0.37; p =
0.005) and -DRB1*13 (OR 0.34; p = 0.002) was rarer in
Borreliosis patients and significantly more frequent in con-
trols.
ACKNOWLEDGEMENTS
This work was supported by the European Social Fund
(ESF) project “Support for doctoral study programme and
scientific degree receiving in Rîga Stradiòð University,
agreement No. 2009/0147/1DP/1.1.2.1.2/09/IPIA/ VIAA/
009”.
REFERENCES
Abramowicz, M. (2000). Treatment of Lyme disease. Med. Letter, 42,
37–39.
Anonymous (2008). Reported Cases of Lyme Disease by Year, 2007, United
States, 1991–2006. September 27, 2007 (cited 2008 March 26); Available
at: http://www.cdc.gov/ncidod/dvbid/lyme/ld_UpClimbLymeDis.htm.
Anonymous (2012). Categorical data analysis using the SAS system.
Anonymous (2014). Statistical data on incidence of infectious diseases in
Latvia 2014. Available at:
http://www.ecdc.europa.eu/en/publications/publications/tbe-in-eu-
efta.pdf (accessed 03.06.2016).
Auwaerter, P. G., Aucott, J., Dumler, J. S. (2004). Lyme borreliosis (Lyme
disease): Molecular and cellular pathobiology and prospects for preven-
tion, diagnosis and treatment. Expert Rev. Mol. Med., 6 (2), 1–22.
Auwaerter, P. G. (2007). Point: antibiotic therapy is not the answer for pa-
tients with persisting symptoms attributable to Lyme disease. Clin. Infect.
Dis., 45 (2), 143–148.
Bateman, H., Sigal, L. (2000). Update on Lyme Carditis. Curr. Infect. Dis.
Rep., 2 (4), 299–301.
Bunikis, J., Barbour, A. G. (2002). Laboratory testing for suspected Lyme
disease. Med. Clin. North Amer., 86 (2), 311–340.
Fallon, B. A., Keilp, J. G., Corbera, K. M., Petkova, E., Britton, C. B.,
Dwyer, E., Slavov, I., Cheng, J., Dobkin, J., Nelson, D. R., Sackeim, H. A.
(2008). A randomized, placebo-controlled trial of repeated IV antibiotic
therapy for Lyme encephalopathy. Neurology, 70 (13), 992–1003.
Feder, H. M. Jr, Johnson, B. J. B., O’Connell, S., Shapiro, E. D., Steere, A.
C., Wormser, G. P. (2007). The Ad Hoc International Lyme Disease
Group. A critical appraisal of Chronic Lyme Disease. New Engl. J. Med.,
357, 1422–1430.
Fleming, R. V., Marques, A. R., Klempner, M. S., Schmid, C. H., Dally, L.
G., Martin, D. S., Philipp, M. T. (2004). Pre-treatment and post-treatment
assessment of the C(6) test in patients with persistent symptoms and a his-
tory of Lyme borreliosis. Eur. J. Clin. Microbiol. Infect. Dis., 23 (8),
615–618.
Halperin, J. J. (2003). Lyme disease and the peripheral nervous system. Mus-
cle Nerve, 28 (2), 133–143.
Halperin, J. J. (2005). Central nervous system Lyme disease. Curr. Neurol.
Neurosci. Rep., 5 (6), 446–452.
Halperin, J. J, Shapiro, E. D., Logigian, E., Belman, A. L., Dotevall, L.,
Wormser, G. P., Krupp, L., Gronseth, G., Bever, C. T. Jr. (2007). Practice
parameter: Treatment of nervous system Lyme disease (An evidence-based
review). Report of the Quality Standards Subcommittee of the American
Academy of Neurology. Neurology, 69, 91–102.
Hu, L. (2005). Lyme arthritis. Infect. Dis. Clin. North Amer., 19 (4),
947–961.
Klitz, W., Maiers, M., Spellman, S., Baxter-Lowe, L. A., Schmeckpeper, B.,
Williams, T. M., Fernandez-Vina, M. (2003). New HLA haplotype fre-
quency reference standards: High-resolution and large sample typing of
HLA DR-DQ haplotypes in a sample of European Americans. Tissue Anti-
gens. 62, 296–307.
Kotsch, K., Wehling, J., Blasczyk, R. (1999). Sequencing of HLA class II
genes based on the conserved diversity of the non-coding regions: Se-
quencing based typing of HLA-DRB genes. Tissue Antigens, 53, 486–497.
Mullegger, R. R. (2004). Dermatological manifestations of Lyme
borreliosis. Eur. J. Dermatol., 14, 296–309.
Nadelman, R. B., Nowakowski, J., Fish, D., Falco, R. C., Freeman, K.,
McKenna, D., Welch, P., Marcus, R., Aguero-Rosenfeld, M. E., Dennis, D.
T., Wormser, G. P. (2001). Tick Bite Study Group. Prophylaxis with sin-
gle-dose doxycycline for the prevention of Lyme disease after an Ixodes
scapularis tick bite. New Engl. J. Med., 345, 79–84.
Nowakowski, J., Nadelman, R. B., Sell, R., McKenna, D., Cavaliere, L.
F., Holmgren, D., Gaidici, A., Wormser, G. P. (2003). Long-term fol-
low-up of patients with culture-confirmed Lyme disease. Amer. J. Med.,
115, 91–96.
Olerup, O., Aldener, A., Fogdell, A. (1993). HLA-DQB1 and -DQA1 typing
by PCR amplification with sequence-specific primers (PCR-SSP). Tissue
Antigens, 41 (3), 119–134.
Oksi, J., Nikoskelainen, J., Hiekkanen, H., Lauhio, A., Peltomaa, M.,
Pitkäranta, A., Nyman, D., Granlund, H., Carlsson, S. A., Seppälä, I.,
Valtonen, V., Viljanen, M. (2007). Duration of antibiotic treatment in dis-
seminated Lyme borreliosis: A double-blind, randomized, placebo-con-
trolled, multicenter clinical study. Eur. J. Clin. Microbiol. Infect. Dis., 26,
571–581.
218 Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.
Philipp, M. T., Wormser, G. P., Marques, A. R., Bittker, S., Martin, D. S.,
Nowakowski, J.,. Dally, L. G. (2005). A decline in C6 antibody titer occurs
in successfully treated patients with culture-confirmed early localized or
early disseminated Lyme Borreliosis. Clin. Diagn. Lab. Immunol., 12 (9),
1069–1074.
Piacentino, J..D., Schwartz, B. S. (2002). Occupational risk of Lyme disease:
An epidemiological review. Occup. Environ. Med., 59 (2), 75–84.
Qureshi, M. Z., New, D., Zulqarni, N. J., Nachman, S. (2002). Overdiagnosis
and overtreatment of Lyme disease in children. Pediatr. Infect. Dis. J., 21,
12–14.
Schoen, R. T., Sikand, V. K., Caldwell, M. C., Van Hoecke, C., Gillet, M.,
Buscarino, C., Parenti, D. L. (2000). Safety and immunogenicity profile of
a recombinant outer surface protein A Lyme disease vaccine: Clinical trial
of a 3-dose schedule at 0, 1, and 2 months. Clin. Therapeutics, 22, 315–325.
Seltzer, E. G., Gerber, M. A., Cartter, M. L., Freudigman, K., Shapiro, E. D.
(2000). Long-term outcomes of persons with Lyme disease. The Journal of
the American Medical Association (JAMA), 283, 609–616.
Sikand, V. K., Halsey, N., Krause, P. J., Sood, S. K., Geller, R., Van Hoecke,
C., Buscarino, C., Parenti, D. (2001). Pediatric Lyme Vaccine Study
Group. Safety and immunogenicity of a recombinant Borrelia burgdorferi
outer surface protein A vaccine against Lyme disease in healthy children
and adolescents: A randomized controlled trial. Pediatrics, 108, 123–128.
Smith, R. P., Schoen, R. T., Rahn, D. W., Sikand, V. K., Nowakowski,
J., Parenti, D. L., Holman, M. S., Persing, D. H., Steere, A. C. (2002). Clini-
cal characteristics and treatment outcome of early Lyme disease in patients
with microbiologically confirmed erythema migrans. Ann. Intern. Med.,
136, 421–428.
Steere, A. C. (2001). Lyme disease. New Engl. J. Med., 345, 115–125.
Steere, A. C., Gross, D, Meyer, A. L., Huber, B. T. (2001). Autoimmune
mechanisms in antibiotic treatment-resistant Lyme arthritis. J. Auto-
immun., 16, 263–268.
Steere A. C., Dhar. A, Hernandez, J., Fischer, P. A., Sikand, V. K., Schoen,
R. T., Nowakowski, J., McHugh, G., Persing, D. H. (2003). Systemic
symptoms without erythema migrans as the presenting picture of early
Lyme disease. Amer. J. Med., 114, 58–62.
Steere, A. C., Falk, B., Drouin, E. E., Baxter-Lowe, L. A., Hammer, J.,
Nepom, G. T. (2003). Binding of outer surface protein A and human lym-
phocyte function-associated antigen 1 peptides to HLA-DR molecules as-
sociated with antibiotic treatment-resistant Lyme arthritis. Arthritis
Rheum., 48, 534–540.
Steere, A. C., McHugh, G., Suarez, C., Hoitt, J., Damle, N., Sikand, V. K.
(2000). Prospective study of coinfection in patients with erythema migrans.
Clin. Infect. Dis., 36, 1078–1081.
Steere, A. C., Klitz ,W., Drouin, E. E., Falk, B. A., Kwok, W. W., Nepom, G.
T. Baxter-Lowe, L. A. (2006). Antibiotic-refractory Lyme arthritis is asso-
ciated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J.
Exp. Med., 203, 961–971.
Stricker, R. B. (2007). Counterpoint: Long-term antibiotic therapy improves
persistent symptoms associated with Lyme disease. Clin. Infect. Dis., 45,
149–157.
Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., Halperin, J. J., Steere, A. C.,
Klempner, M. S., Krause, P. J., Bakken, J. S., Strle, F., Stanek, G.,
Bockenstedt, L., Fish, D., Dumler, J. S., Nadelman, R. B. (2006). The clini-
cal assessment, treatment and prevention of Lyme disease, human
granulocytic Anaplasmosis, and Babesiosis: Clinical practice guidelines by
the Infectious Diseases Society of America. Clin. Infect. Dis., 43,
1089–1134.
Wormser, G. P., Nadelman, R. B., Dattwyler, R. J., Dennis, D. T., Shapiro, E.
D., Steere, A. C., Rush, T. J., Rahn, D. W., Coyle, P. K., Persing, D. H.,
Fish, D., Luft, B. J. (2000). Infectious Diseases Society of America Prac-
tice Guidelines for the Treatment of Lyme Disease. Clin. Infect. Dis., 31
(Suppl 1), S1–S14. (also available at: www.idsociety.org).
Wormser, G. P., Ramanathan, R., Nowakowski, J., McKenna, D., Holmgren,
D., Visintainer, P., Dornbush, R., Singh, B., Nadelman, R. B. (2003). Du-
ration of antibiotic therapy for early Lyme disease: A randomized, dou-
ble-blind, placebo-controlled trial. Ann. Intern. Med., 138, 697–704.
IMÛNÌENÇTISKÂS IZPAUSMES LAIMBORELIOZES GADÎJUMÂ
Ðajâ pçtîjumâ mçs noteicâm HLA DRB1 Lyme borreliosis (LB) pacientiem Latvijâ. Pçtîjuma grupa un kontroles grupa tika atlasîtas un
sadalîtas lîdzîgi pçc vecuma, dzimuma, etniskâs piederîbas un atðíîrâs ar Borrelia burgdorferi klâtbûtni. HLA-DRB1*07 (OR 3.52; p =
0.001), HLA-DRB1*15 (OR 3.02; p = 0.001) un HLA-DRB1 *17 (03) (OR 2.63; p = 0.001) sastopamîbas bieþums bija ievçrojami lielâks LB
pacientiem nekâ kontroles grupai. Alçles DRB1*11 (OR 0.37; p = 0.005) un DRB1*13 (OR 0.34; p = 0.002) bija retâk LB pacientiem un
ievçrojami vairâk kontroles grupai.
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